Piramal gears up to take Alzheimer's imaging agent to market through IBA deal
This article was originally published in Scrip
IBA Molecular, a global leader in the nuclear medicine segment, is to manufacture and distribute Piramal Imaging's recently acquired late-stage diagnostic imaging agent, 18F-florbetaben, in Europe and the US.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.